Literature DB >> 30855755

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

Hazel O'Sullivan1, Dearbhaile Collins1, Seamus O'Reilly1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30855755     DOI： 10.1056/NEJMc1900150

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  7 in total

1.  Supervised Machine Learning Predictive Analytics For Triple-Negative Breast Cancer Death Outcomes.

Authors:  Yucan Xu; Lingsha Ju; Jianhua Tong; Chengmao Zhou; Jianjun Yang
Journal:  Onco Targets Ther       Date:  2019-11-01       Impact factor: 4.147

2.  Development and validation of a nomogram in survival prediction among advanced breast cancer patients.

Authors:  Jianli Zhao; Yaping Yang; Danmei Pang; Yunfang Yu; Xiao Lin; Kai Chen; Guolin Ye; Jun Tang; Qian Hu; Jie Chai; Zhuofei Bi; Linxiaoxiao Ding; Wenjing Wu; Yinduo Zeng; Xiujuan Gui; Donggeng Liu; Herui Yao; Ying Wang
Journal:  Ann Transl Med       Date:  2020-11

3.  Landscape of Immune Microenvironment Under Immune Cell Infiltration Pattern in Breast Cancer.

Authors:  Qianhui Xu; Shaohuai Chen; Yuanbo Hu; Wen Huang
Journal:  Front Immunol       Date:  2021-08-27       Impact factor: 7.561

Review 4.  Revisiting Hepatic Artery Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma.

Authors:  Ching-Tso Chen; Tsung-Hao Liu; Yu-Yun Shao; Kao-Lang Liu; Po-Chin Liang; Zhong-Zhe Lin
Journal:  Int J Mol Sci       Date:  2021-11-28       Impact factor: 5.923

5.  Chidamide Reverses Fluzoparib Resistance in Triple-Negative Breast Cancer Cells.

Authors:  Xinyang Li; Xiang Yuan; Ziming Wang; Jing Li; Zhiwei Liu; Yukun Wang; Limin Wei; Yuanpei Li; Xinshuai Wang
Journal:  Front Oncol       Date:  2022-02-18       Impact factor: 6.244

Review 6.  Exosomes and breast cancer drug resistance.

Authors:  Xingli Dong; Xupeng Bai; Jie Ni; Hao Zhang; Wei Duan; Peter Graham; Yong Li
Journal:  Cell Death Dis       Date:  2020-11-17       Impact factor: 8.469

7.  FBI-1 enhanced the resistance of triple-negative breast cancer cells to chemotherapeutic agents via the miR-30c/PXR axis.

Authors:  Hua Yang; Lili Ren; Yanan Wang; Xuebing Bi; Xiaoli Li; Ming Wen; Qian Zhang; Yang Yang; Youchao Jia; Yumiao Li; Aimin Zang; Yaning Wei; Guanghai Dai
Journal:  Cell Death Dis       Date:  2020-10-13       Impact factor: 8.469
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.